Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027497 (nausea)
 23,468 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A total of 56 women 18-45 years of age weighing 40-100 kg schedules for elective laparoscopic sterilization with or without uterine curettage were randomized into 2 groups, and 25 were subsequently analyzed in each data set. They received either 2 suppositories of 100 mg indomethacin each (Indocid) (Group 1), or 2 identical placebo suppositories (Group 2). At the same time, all patients received a premedication of temazepam 10 mg orally 2 hours preoperatively. General anaesthesia consisted of droperidol 1.25 mg IV, fentanyl 1.5 mcg/kg IV. Filshie clips were used exclusively. Analgesia consisted of 25 mg aliquots of pethidine iv in the recovery room and on the ward by using 1.0 mg.kg of in pethidine, 2-hourly if requested. There was no difference between groups with respect to patient characteristics. In the recovery room, the rating of no pain was lower with 28% in the indomethacin group (group 1) versus 18% in group 2, but the difference was not significant (p = .29). At 30 minutes postoperatively, 54% of those receiving indomethacin compared to 47% of the placebo groups had a pain score less than 30 (p = .09); and 96% compared to 72% had a score less than 70 (p = .07), but these differences were not significant. 48% in group 1 and 32% in group 2 did not require any postoperative pethidine (p = .39). The mean dosage of pethidine used was 24 mg +or- 27 mg in the indomethacin group and 42 mg +or- 44 mg in the placebo group. The Wilcoxon Rank Sum test also showed a nonsignificant trend for lower pethidine dose requirements in the indomethacin group, and in the Log Rank test this difference almost reached statistical significance. The incidence of preoperative (postmedication) nausea, headache and abdominal pain did not differ between the groups. There was a consistently lower incidence of postoperative symptoms or side-effects in the indomethacin group, but this was not statistically significant.
 ...
PMID:Preoperative rectal indomethacin for analgesia after laparoscopic sterilisation. 138 3

Suprofen (Suprol-Cilag S.p.A.), a prostaglandin synthetase inhibitor, was tested in a double-blind crossover design on 28 women whose IUDs caused them pain or increased menstrual bleeding. The subjects had worn either a Gravigard (18 women) or a Copper T (10) for 6 to 10 months. Each subject was observed for the first month, and took either placebo or Suprofen during the next menses, followed by the alternative for the third cycle. They took 20 mg Suprofen 4 times daily, at the first sign of bleeding and or pain, then 3 times daily thereafter, for the duration of symptoms or up to 7 days. Before treatment, 71% had severe bleeding, 18% had moderate bleeding and 11% had slightly increased bleeding. During Suprofen, 43% obtained a strong decrease in menstrual blood loss, 36% had a moderate decrease and 7% had a slight decrease. Placebo decreased bleeding moderately in 2. Pain was moderate to intense in 26 women and slight or none in 2 before treatment. With Suprofen, pain decreased moderately or greatly in 23 and slightly or not at all in 5 women. Placebo improved pain moderately in 1 subject. Reported side effects of the drug were stomach cramps in 1 and nausea and headaches in 2 women. In this study, when the subjects were categorized by degree of symptoms, the prostaglandin antagonist was more effective in those complaining of more severe bleeding and pain.
 ...
PMID:Action of a prostaglandin synthetase inhibitor on IUD associated uterine bleeding. 310 27

The analgesic effect and the tolerability of alpha-methyl-4-(2-thienyl-carbonyl)phenylacetic acid (suprofen, Suprol) syrup 200 mg and metamizole syrup 500 mg were compared in a randomized single-blind study including hospitalized patients with severe to moderate chronic pain. The 2 treatment groups consisted of 30 subjects each and were homogeneous as to the demographic data. Pain intensity was appreciated by the investigator prior to the treatment and on days 2, 3, and 5 of the study; pain relief was assessed on days 2, 3, and 5 of the therapy. Although pain intensity was on treatment with suprofen more markedly reduced than with metamizole, there was no statistically significant difference between the 2 treatment groups (chi 2-test). The Mann-Whitney test revealed that on days 3 and 5 pain relief with suprofen was significantly superior to that with metamizole. According to the investigator's final global evaluation, suprofen syrup 200 mg had very good to good effect in 70% of the cases, whereas the effectiveness of metamizole was rated good to very good in 44%. Side-effects manifesting themselves as gastric irritation and nausea were recorded for 3 patients on suprofen and 2 subjects on metamizole.
 ...
PMID:Controlled single-blind clinical study of suprofen syrup versus metamizole syrup. 353 86

This double-blind, randomized study was designed to evaluate the use of indomethacin (Indocid, MSD) following caesarean delivery performed under spinal anaesthesia. Thirty ASA I-II women presenting for elective caesarean were recruited. Spinal anaesthesia was performed in a standard manner using hyperbaric bupivacaine, fentanyl and morphine. At the completion of surgery, subjects were administered two rectal suppositories, followed by 12-hourly suppositories for six doses (three days). The study group received 100 mg indomethacin suppositories and controls were given placebo (Anusol). Data collected included Visual Analog Scale (VAS) pain scores at rest and with movement, VAS scores for nausea and itch, and analgesic use. Demographic data were similar in the two groups. Median time to first analgesia (TTFA) was nine hours in the control group v. 39.5 hours in the indomethacin group (P < 0.003). Additional analgesic requests throughout the postoperative period were less in women who received indomethacin: 4 v 11 (P < 0.001). Women who received indomethacin had significantly less pain on the first postoperative day, especially on movement: mean VAS 1.4 v 5.1 (P < 0.00001). There were no reported adverse neonatal or maternal effects from the use of indomethacin. Rectal indomethacin use following caesarean delivery leads to significantly improved pain relief compared with placebo. The combination of spinal morphine and rectal indomethacin leads to high-quality postoperative analgesia.
 ...
PMID:Rectal indomethacin potentiates spinal morphine analgesia after caesarean delivery. 878 53